Pfizer PFE Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 293.4%+1.2pp | 292.1%+2.4pp | 289.7%+5.7pp | 284.1%+13.9pp | 270.1%+14.2pp | |
| Efficiency | ||||||
| Asset turnover | 1.2×0.0× | 1.2×0.0× | 1.2×0.0× | 1.2×0.0× | 1.1×0.0× | |
| Inventory turnover | 26.3×+0.8× | 25.6×+1.4× | 24.1×-2.5× | 26.6×+1.4× | 25.2×+0.4× | |
| Liquidity | ||||||
| Current ratio | 4.8×0.0× | 4.9×0.0× | 4.9×+0.3× | 4.6×+0.3× | 4.3×+0.2× | |
| Quick ratio | 4.6×0.0× | 4.6×0.0× | 4.6×+0.3× | 4.3×+0.3× | 4×+0.2× | |
| Cash ratio | 0.2×0.0× | 0.2×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Leverage | ||||||
| Debt-to-equity | 2.9×0.0× | 2.8×+0.1× | 2.8×0.0× | 2.8×0.0× | 2.8×0.0× | |
| Debt-to-assets | 1.2×0.0× | 1.2×0.0× | 1.2×0.0× | 1.2×0.0× | 1.2×0.0× | |
| Per Share | ||||||
| Book value per share | $62.64-0.2% | $62.74-0.5% | $63.08+0.1% | $63.02+0.2% | $62.87-0.6% | |
| Valuation | ||||||
| Market capitalization | $584.38B+2.8% | $568.37B-1.5% | $577.14B-3.2% | $596.25B-3.3% | $616.32B-2.1% | |
| Enterprise value | $833.43B+2.3% | $814.65B-0.7% | $820.05B-2.3% | $839.49B-2.3% | $859.63B-1.7% | |
| Price / sales | 9.3×+0.2× | 9×-0.1× | 9.1×-0.4× | 9.5×-0.7× | 10.2×-0.5× | |
| Price / book | 6.5×+0.2× | 6.3×-0.1× | 6.4×-0.2× | 6.6×-0.2× | 6.9×-0.1× | |
| EV / sales | 13.2×+0.3× | 13×0.0× | 13×-0.4× | 13.4×-0.8× | 14.2×-0.6× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Pfizer's ratios come from?
- Every ratio is computed from Pfizer's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
